Cell Therapeutics Announces Resignation of Chief Medical Officer

       Cell Therapeutics Announces Resignation of Chief Medical Officer

PR Newswire

SEATTLE, June 28, 2013

SEATTLE, June 28, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI")
(NASDAQ: CTIC and MTA: CTIC) today announced the resignation of Steven E.
Benner, M.D., M.H.S., Senior Vice President, Chief Medical Officer and Chief
Compliance Officer for personal reasons. Nancy Boman, M.D., Ph.D., Senior Vice
President, Clinical Development and Regulatory Affairs, is expected to assume
interim responsibility for the oversight of CTI's ongoing and planned clinical
trials of compounds for the treatment of blood cancers. CTI has engaged a
search firm to assist in an external search for a new Chief Medical Officer
and will appoint a new Chief Compliance Officer. Immediately prior to his
resignation, based on public records, Dr. Benner beneficially owned 396,705
shares of CTI's common stock.

"Steve has established a strong leadership team in the clinical organization
that is focused on advancing our two ongoing late-stage clinical programs for
pacritinib and PIXUVRI® (pixantrone). We acknowledge and thank Steve for his
significant contributions to these programs and wish him the very best in his
future endeavors," said James A. Bianco, M.D., President and CEO of CTI.

Dr. Bianco added, "As we move toward initiating the second planned Phase 3
clinical trial evaluating pacritinib, our JAK2/FLT3 inhibitor for the
treatment of patients with myelofibrosis later this year, we are confident
that the clinical and regulatory team we have in place will continue to
execute and our development plans will remain on track."

AboutCell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the
development and commercialization of an integrated portfolio of oncology
products aimed at making cancer more treatable. CTI is headquartered
inSeattle, WA. For additional information and to sign up for email alerts
and get RSS feeds, please visitwww.CellTherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements that are made pursuant
to the Safe Harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the Company's
development. Such statements involve a number of risks and uncertainties, the
outcome of which could materially and/or adversely affect actual future
results and the trading price of our securities. Specifically, the risks and
uncertainties include risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and CTI and its
product candidates in particular, including the risk that the second Phase 3
clinical trial of pacritinib will not occur as planned; determinations by
regulatory, patent and administrative governmental authorities, competitive
factors, technological developments, costs of developing products; and the
risk factors listed or described from time to time in CTI's filings with the
Securities and Exchange Commission including, without limitation, CTI's most
recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by
law, CTI does not intend to update or alter its forward-looking statements
whether as a result of new information, future events, or otherwise.

CTI Media and Investor Contacts:

Monique Greer
+1 206.272.4343

Ed Bell
+1 206.282.7100

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
Press spacebar to pause and continue. Press esc to stop.